Coya Therapeutics (COYA) Non-Current Deffered Revenue (2023 - 2026)

Coya Therapeutics has disclosed Non-Current Deffered Revenue across 4 years of filings, most recently posting $519636.0 for Q2 2026.

• In Q2 2026, Non-Current Deffered Revenue fell 18.95% year-over-year to $519636.0; the TTM figure through Jun 2026 stood at $519636.0 (down 18.95% YoY), while the FY2025 annual figure was $1.1 million, up 11.07% from the prior year.
• Non-Current Deffered Revenue came in at $519636.0 for Q2 2026 at Coya Therapeutics, down from $754198.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2024 to a low of $519636.0 in Q2 2026.
• Average Non-Current Deffered Revenue over 4 years is $821043.9, with a median of $754198.0 recorded in 2026.
• Year-over-year, Non-Current Deffered Revenue surged 64.52% in 2024 and fell 25.16% in 2025.
• Over 4 years, Non-Current Deffered Revenue stood at $574685.0 in 2023, then surged by 64.52% to $945447.0 in 2024, then climbed by 11.07% to $1.1 million in 2025, then tumbled by 50.52% to $519636.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $519636.0 in Q2 2026, $754198.0 in Q1 2026, and $1.1 million in Q4 2025.